Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

Inclusion Criteria: * Japanese male or female patients * Presence of active subfoveal and/or juxtafoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Exclusion Criteria: * History of or active periocular, ocular, or intraocular infection * Previous use of ocular anti-angiogenic therapy within 1 month (ranibizumab), 6 weeks (pegaptanib), or 2 months (bevacizumab and aflibercept) of Day 1 for the treatment of neovascular AMD or neovascular eye diseases other than AMD * Macular hemorrhage that involves the center of fovea in the study eye * Previous use of verteporfin photodynamic therapy (PDT) or previous therapeutic radiation in the region * Treatment with ocular corticosteroid injections or implants within 6 months in the study eye * History or evidence of eye surgery: Pars plana vitrectomy, Submacular surgery or other surgical interventions for AMD, Incisional glaucoma surgery or Cataract or refractive surgery within the last 3 months * AMD or neovascular eye diseases other than AMD in the non-study eye that require anti-VEGF treatment